Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | GBA1 | P04062 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | MMP1 | P03956 | 1/20 | 0.52 |
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | MMP9 | P14780 | 1/20 | 0.52 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6020322 | 0.84 | ALDH1A1 (0.60) | ALDH1A1MEN1KMT2ACA12CA9 | |
| SCHEMBL20451437 | 0.83 | SIGMAR1 (0.54) | GAACYP19A1CA2CA1MMP1 | |
| SCHEMBL3306367 | 0.82 | ALDH1A1 (0.66) | ALDH1A1MEN1KMT2ACA12CA9 | |
| SCHEMBL10389233 | 0.82 | ALDH1A1 (0.55) | ALDH1A1CA12CA9GBA1CYP1A2 | |
| SCHEMBL2624207 | 0.81 | ALDH1A1 (0.63) | ALDH1A1MEN1KMT2ACA12CA9 | |
| SCHEMBL5567042 | 0.79 | ALDH1A1 (0.75) | ALDH1A1MEN1KMT2ACA12CA9 | |
| SCHEMBL19466252 | 0.79 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2ACA12CA9 | |
| SCHEMBL17529225 | 0.79 | CA2 (0.50) | ALDH1A1CA12CA9CYP1A2CYP3A4 | |
| SCHEMBL10644344 | 0.79 | CA2 (0.59) | ALDH1A1MEN1KMT2ACA12CA9 | |
| SCHEMBL8213969 | 0.78 | ALDH1A1 (0.72) | ALDH1A1MEN1KMT2ACA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115246789-B | Preparation method of nodestrat | 上海医药集团青岛国风药业股份有限公司 | 2023-10-17 | — | — | CN | claimed |
| CN-115246789-A | Preparation method of nodispat | 上海医药集团青岛国风药业股份有限公司 | 2022-10-28 | — | — | CN | claimed |
| CN-110272386-B | Preparation method of nodispat | 上海医药集团青岛国风药业股份有限公司 | 2022-09-09 | — | — | CN | claimed |
| WO-2019174631-A1 | METHOD FOR PREPARING NORSTAT | 上海医药集团股份有限公司 | 2019-09-19 | — | — | WO | claimed |
| CN-115246789-B | Preparation method of nodestrat | 上海医药集团青岛国风药业股份有限公司 | 2023-10-17 | — | — | CN | disclosed |
| CN-115246789-A | Preparation method of nodispat | 上海医药集团青岛国风药业股份有限公司 | 2022-10-28 | — | — | CN | disclosed |
| CN-110272386-B | Preparation method of nodispat | 上海医药集团青岛国风药业股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| WO-2019174631-A1 | METHOD FOR PREPARING NORSTAT | 上海医药集团股份有限公司 | 2019-09-19 | — | — | WO | disclosed |
| EP-2513110-B1 | 1,7-DIAZACARBAZOLES AND THEIR USE IN THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2018-12-05 | — | — | EP | disclosed |
| US-9440976-B2 | 1,7-diazacarbazoles and methods of use | GENENTECH, INC. (US) | 2016-09-13 | — | — | US | disclosed |
| US-9216980-B2 | Methods of use of diazacarbazoles for treating cancer | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-9216980-B2 | Methods of use of diazacarbazoles for treating cancer | GENENTECH, INC. (US) | 2015-12-22 | — | — | US | disclosed |
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | GSK LLC | 2011-01-06 | — | — | US | disclosed |
| US-7812016-B2 | Naphthyridine integrase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2010-10-12 | — | — | US | disclosed |
| WO-2009151598-A1 | DIAZACARBAZOLES AND METHODS OF USE | GENENTECH, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
| EP-1622615-A4 | NAPHTHYRIDINE INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | GSK LLC | 2007-06-21 | — | — | US | disclosed |
| EP-1622615-A2 | NAPHTHYRIDINE INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004101512-A2 | NAPHTHYRIDINE INTEGRASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-11-25 | — | — | WO | disclosed |
| US-5990353-A | DEMETALLIZING AN ARYLSULFONAMIDE ALKALI METAL SALT WITH AN AROMATIC ISOCYANATE COMPOUND IN AT LEAST ONE SOLVENT; USE AS A COLOR DEVELOPER FOR A THERMAL RECORDING MATERIAL WITH IMPROVED OIL RESISTANCE AND NONPLASTICIZED | YAMAMOTO CHEMICALS, INC. (JP) | 1999-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003794-A1 | Naphthyridine Integrase Inhibitors | PCNA, SAMHD1, NTPCR | ALDH1A1 2955/4885MEN1 4802/4885KMT2A 1772/4885 |
| US-20070142365-A1 | Naphthyridine integrase inhibitors | PCNA, SAMHD1, NTPCR | ALDH1A1 2955/4885MEN1 4802/4885KMT2A 1772/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.